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ntianginal Efficacy of Ranolazine
hen Added to Treatment With Amlodipine
he ERICA (Efficacy of Ranolazine in Chronic Angina) Trial
eter H. Stone, MD, FACC,* Nikolay A. Gratsiansky, MD,† Alexey Blokhin, MD,‡ I-Zu Huang, MD,§
ixin Meng, MS, MPH,§ for the ERICA Investigators
oston, Massachusetts; Moscow, Russia; and Palo Alto, California
OBJECTIVES The purpose of this study was to determine if ranolazine improves angina in stable coronary
patients with persisting symptoms despite maximum recommended dose of amlodipine.
BACKGROUND Ranolazine is a unique antianginal agent that has been effective in stable angina, but it has not
been studied in the setting of maximum recommended doses of conventional antianginal
agents.
METHODS Stable patients with coronary disease and 3 anginal attacks per week despite maximum
recommended dosage of amlodipine (10 mg/day) were randomized to 1,000 mg ranolazine or
placebo twice a day for 6 weeks. Primary end point was the frequency of angina episodes per
week during the double-blind treatment phase. Efficacy was also assessed by nitroglycerin
consumption per week and the Seattle Angina Questionnaire (SAQ). Adjustment for
multiple testing of secondary end points used a hierarchic closed testing procedure. Efficacy
was assessed in subgroups based on baseline angina frequency, concomitant long-acting
nitrate use, gender, and age. Safety was assessed by adverse events and electrocardiogram
evaluations.
RESULTS A total of 565 patients were randomized: 281 patients to ranolazine and 284 patients to
placebo. Baseline characteristics were similar between treatment groups. At baseline, angina
frequency averaged 5.63  0.18 episodes/week, and nitroglycerin consumption averaged 4.72
 0.21 tablets/week. Compared with placebo, ranolazine significantly reduced frequency of
angina episodes (2.88  0.19 on ranolazine vs. 3.31  0.22 on placebo; p  0.028) and
nitroglycerin consumption (2.03  0.20 on ranolazine vs. 2.68  0.22; p  0.014), with
treatment effect that appeared consistent across subgroups. The median angina weekly
episode rate at baseline was 4.5 per week. Subgroup analysis showed statistically significant
reductions of angina frequency, nitroglycerin use, and SAQ angina frequency for patients
with a baseline frequency 4.5 per week but only of angina frequency for those with baseline
frequency 4.5 per week. Patients with more frequent angina appeared to have a more
pronounced treatment effect. No hemodynamic changes were observed. Ranolazine was well
tolerated.
CONCLUSIONS Ranolazine significantly reduced frequency of angina and nitroglycerin consumption com-
pared with placebo and was well tolerated. (The ERICA [Efficacy of Ranolazine In Chronic
Angina] Trial; http://clinicaltrials.gov; NCT00091429) (J Am Coll Cardiol 2006;48:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.05.044566–75) © 2006 by the American College of Cardiology Foundation
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wngina affects approximately 6.4 million Americans with
table coronary disease (CAD) (1). Currently available
ntianginal agents in the U.S. include beta-blockers,
alcium-channel blockers, and long-acting nitrates (LANs)
2,3). Despite treatment with conventional agents and/or
evascularization, many patients remain symptomatic. One
From the Cardiovascular Division, Brigham and Women’s Hospital, Boston,
assachusetts; †Center for Atherosclerosis, Institute of Physicochemical Medicine,
oscow, Russia; ‡Outpatient Clinic of Medical Center of Russian Federation
resident’s Management Department, Moscow, Russia; and §CV Therapeutics, Palo
lto, California. Supported by CV Therapeutics, Palo Alto, California. Dr. Stone has
erved on an advisory board and is a consultant for CV Therapeutics, has received
rant support from Pfizer, Boston Scientific Corporation, and Novartis, and has given
ectures for Pfizer. Prof. Gratsiansky and Dr. Blokhin were investigators for the
RICA study, and their institutions received financial support for their participation.
r. Huang and Ms. Meng are employees of CV Therapeutics.r
Manuscript received April 1, 2006; revised manuscript received May 18, 2006,
ccepted May 22, 2006.ear after coronary artery bypass grafting or percutaneous
oronary intervention, 25% to 60% of patients continue to
ave angina and require antianginal medication (4,5). Con-
entional pharmacologic therapies exert an anti-ischemic
ffect by lowering determinants of myocardial O2 demand
See page 576
heart rate, myocardial contractility, or wall stress). Al-
hough combination regimens of conventional antianginal
herapies may provide incremental efficacy (6–9), such
ombination regimens may lead to excessive side effects
10–12) or to a decrease in anti-ischemic efficacy (13).
Availability of a new agent that could be used in concert
ith other antianginal therapies without causing excessive
eductions in myocardial O2 demand determinants would be
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August 1, 2006:566–75 Ranolazine for Stable Anginaf enormous value. Ranolazine is a new antianginal agent
ith a novel mechanism of action that involves selective
nhibition of the late sodium current. This action reduces
he magnitude of ischemia-induced sodium and calcium
verload and thereby improves myocardial function as well
s myocardial perfusion (14–16).
In stable CAD patients, ranolazine has demonstrated
nti-ischemic efficacy alone (17–19) and as part of a com-
ination regimen with submaximal doses of other antiangi-
al agents (20) without significantly affecting heart rate or
all stress (17–21). However, ranolazine has not been
tudied in a combination regimen with a maximum recom-
ended dosage of a conventional antianginal agent. The
oal of the ERICA (Efficacy of Ranolazine In Chronic
ngina) trial was to determine if ranolazine could reduce
ngina in patients with persisting angina despite treatment
ith maximum recommended daily dosage of amlodipine
10 mg/day) over a 6-week period. Amlodipine was selected
s the conventional antianginal agent to be studied at
aximum recommended dosage (10 mg/day) in a combi-
ation regimen, because the maximum recommended dos-
ges of other conventional agents, such as atenolol (200
g/day), diltiazem (540 mg/day), or verapamil (480 mg/
ay), were less feasible for routine use.
ETHODS
atients. INCLUSION CRITERIA. Entry criteria included
ge 18 years, documented history of CAD (angiographic
vidence of 60% stenosis of at least 1 major coronary
rtery, history of previous myocardial infarction, and/or a
tress-induced reversible perfusion defect identified by ra-
ionuclide or echocardiographic imaging), chronic stable
ngina 3 months, and 3 episodes of angina per week
uring a 2-week qualification period despite treatment
ith 10 mg/day amlodipine. Patients were required to have
egun 10 mg/day amlodipine at least 2 weeks before
ntering the 2-week qualification period. All other antian-
inal medications were proscribed except LANs and sub-
ingual nitroglycerin as required. Long-acting nitrates were
ermitted if they had been taken at a constant dosage for2
eeks before study entry.
XCLUSION CRITERIA. Patients were excluded if they had
ew York Heart Association functional class IV congestive
eart failure, a history of myocardial infarction or unstable
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
AE  adverse event
CAD  coronary artery disease
ERICA  Efficacy of Ranolazine In Chronic
Angina trial
LAN  long-acting nitrate
SAQ  Seattle Angina Questionnairengina within the previous 2 months, active acute myocar-
F
ritis, pericarditis, hypertrophic cardiomyopathy, or uncon-
rolled hypertension. Patients with a history of torsades de
ointes, those receiving agents known to prolong the QTc
nterval, or who had a QTc interval measurement 500 ms
t study entry were excluded. In addition, patients could not
e receiving inhibitors of cytochrome P450-3A4, or have
linically significant hepatic disease, creatinine clearance
30 ml/min, or chronic illness likely to interfere with
rotocol compliance. Patients taking any digitalis prepara-
ion, perhexiline, trimetazidine, beta-blockers, or calcium-
hannel blockers other than amlodipine were excluded.
atients treated with proscribed antianginal medications
ad to be withdrawn from these agents for 4 weeks before
nitiation of the study drug. Patients could not have partic-
pated in another investigative trial within 30 days before
tudy start.
The study was approved by the institutional review board
t each hospital, and each patient provided written informed
onsent.
tudy design. The study design is illustrated in Figure 1.
ollowing qualification, patients were randomized to receive
ither ranolazine or placebo in a 1:1 ratio. Randomization
as centralized and not stratified by center. Patients were
valuated at 2 and 6 weeks after initiation of full-dose study
rug to assess efficacy and the presence of adverse events
AEs). There were 48 clinical sites (45 in eastern Europe, 2
n the U.S., and 1 in Canada) that enrolled patients from
uly 30, 2004, through February 16, 2005.
Extended-release ranolazine (CV Therapeutics, Palo
lto, California) was supplied as 500 mg tablets and was
dministered double-blind initially at 500 mg twice a day
uring the 1-week run-in phase, and then at 1,000 mg twice
day for the full-dose treatment phase. Amlodipine (Pfizer,
ew York, New York) was supplied as 10 mg tablets and
dministered at the same time each day.
fficacy assessments. The primary efficacy variable was the
eekly average frequency of self-reported angina episodes
uring the 6-week double-blind full-dose treatment phase.
he study staff at each clinical site reviewed the angina and
itroglycerin use diaries with the patient at each study visitigure 1. Study design. BID  twice a day; QD  once per day; RAN 
anolazine.
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Ranolazine for Stable Angina August 1, 2006:566–75o ensure accuracy. The secondary efficacy variables were
verage weekly nitroglycerin consumption rate during the
-week double-blind full-dose treatment phase and the
hange from baseline of the 5 dimensions of the Seattle
ngina Questionnaire (SAQ). Each SAQ dimension (an-
inal frequency, physical limitation, anginal stability, disease
erception, and treatment satisfaction) was scored on a scale
f 0 to 100. Efficacy analyses were conducted in subgroups,
ncluding analyses according to angina severity, concomitant
AN users, gender, and age.
Treatment compliance was monitored through patient-
ecorded anginal diary data and number of tablets dispensed
nd returned.
afety and tolerability assessments. Safety and tolerability
ere assessed by evaluating reported AEs, hemodynamics,
outine clinical laboratory measures, and 12-lead
lectrocardiograms.
tatistical analyses. Efficacy data were analyzed using the
ull analysis set, which included all patients who received at
east 1 dose of study medication during the 6-week treat-
ent phase and had any angina diary data during this
eriod.
The average weekly rates of angina attacks and nitroglyc-
rin consumption over the 6-week treatment phase were
nalyzed using the Cochran-Mantel-Haenzsel mean scores
est, summarizing over strata determined by investigational
ites pooled within geographic regions (1: North America;
: Bulgaria/Romania; 3: Georgia; 4: Moscow, Russia; 5: St.
etersburg, Russia; and 6: other cities in Russia), and using
cores proportional to the sample ranks to reduce the
nfluence of outlying data. Several data points were identi-
ed as extreme outliers (ranging from 47 to 160 angina
ttacks per week) before unblinding. In addition to the
ean, median, 25th percentile, and 75th percentile rates
ere summarized as trimmed means (22), averaging all
bservations except for the top 2% and the bottom 2% to
educe the influence of these outliers.
Primary and secondary efficacy assessment analyses were
onducted in a hierarchic manner; each hypothesis was
ormally tested only if the preceding test was significant at p
0.05. The order of testing for the secondary efficacy
ariables was average weekly rate of nitroglycerin use fol-
owed by dimensions of the SAQ in order from 1 through
. Subgroup analyses were performed according to baseline
ymptom frequency, concomitant LAN use, age, and gen-
er. Between-group comparison for each dimension of the
AQ was conducted using an analysis of covariance model
ith effects for treatment, pooled center, and baseline score.
Comparisons of vital signs between treatment groups
ere conducted at each visit using analysis of variance with
ffects for treatment and pooled center. Supine and standing
ital sign measurements were summarized descriptively
ithin treatment groups. The incidence of AEs and reason
or early withdrawal were summarized by treatment group. 3ESULTS
he disposition of patients throughout the trial is illustrated
n Figure 2. Among the 565 patients randomized, 1 with-
rew during the day on which she was randomized and
ever received double-blind study drug. Among the 564
ho began treatment on ranolazine or placebo in the initial
hase of the study (1 week on double-blind 500 mg
anolazine or placebo), 3 placebo patients were excluded
rom the full analysis set because they did not receive any
ose in the 6-week double-blind treatment phase and also
ad no diary data during this phase; 4 ranolazine patients
ere similarly excluded from the full analysis set, none of
he 4 having any diary data in the 6-week double-blind
reatment phase and 1 of the 4 also not having received a
ose during this phase.
Patient demographics and baseline characteristics includ-
ng medical history are presented in Table 1. Concomitant
edications are listed in Table 2. The baseline characteris-
ics and concomitant medication use appeared similar be-
ween treatment groups.
rimary efficacy results. The average weekly rate of angina
ttacks in ranolazine- versus placebo-treated patients during
he 6-week double-blind treatment phase is shown in Table
and Figure 3A. Patients receiving ranolazine had a
ignificantly lower weekly rate of angina episodes compared
ith patients receiving placebo (trimmed mean 2.88  0.19
s. 3.31 0.22, respectively; p 0.028). As shown in Table
Figure 2. Patient disposition throughout the trial., the conventional means were strongly influenced by the
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ACE  angiotensin-converting enzyme; LAN  long-acting nitrate.
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August 1, 2006:566–75 Ranolazine for Stable Anginaew outliers in the data and may not be representative of the
rue treatment effect. The difference in angina frequency
etween the 75th percentiles was larger than the difference
etween the 25th percentiles, which suggests that the
agnitude of the treatment effect was higher among the
ore symptomatic patients.
econdary efficacy results. As shown in Table 3 and
igure 3B, the average weekly rate of nitroglycerin con-
umption was significantly lower in patients receiving rano-
azine versus those receiving placebo during the 6-week
ouble-blind treatment phase (p  0.014). The nonsignif-
cant (p  0.18) differences in baseline nitroglycerin con-
dipine Ranolazine  Amlodipine
(n  281) p Value
62.0  8.7 0.36*
72/28 0.66†
0.22†
98
1
1
NC
97
3
46 0.72†
5.59  0.21 0.48‡
(n  277)
4.43  0.26 0.18‡
(n  277)
40.6  13.2 0.67*
(n  277)
49.2  17.4 0.93*
(n  271)
54.7  18.0 0.10*
(n  277)
41.6  17.2 0.89*
(n  277)
74.6  14.3 0.46*
(n  277)
100 (36) 0.87†
146 (52) 0.58†
32 (11) 0.69†
99 (35)
15 (5)
0
52 19) 0.82†
11 (4)
218 (78) 0.16†
28 (10) 0.52†
34 (12) 0.095†
39 (14) 0.48†
246 (88) 0.33†
l test, stratifying by pooled site. ‡Cochran-Mantel-Haenszel mean scores test, using
ew York Heart Association; SAQ  Seattle Angina Questionnaire; SD  standardable 1. Demographics, Baseline Characteristics, and Medical History
Placebo  Amlo
(n  283)
emographics
Age (yrs), mean  SD 61.3  9.0
Gender (M/W), % 73/27
Race, %
White 99
Black 1
Asian 0
Geographic region, %
Eastern Europe 97
North America 3
Concomitant use of LANs, % 43
aseline characteristics
Weekly rate of angina attacks, 5.68  0.26
trimmed mean  SE (n  281)
Weekly rate of NTG consumption, 5.02  0.33
trimmed mean  SE (n  281)
SAQ score, mean  SD
Angina frequency 40.0  14.9
(n  281)
Physical limitation 48.9  17.3
(n  276)
Anginal stability 57.2  17.7
(n  281)
Disease perception 41.5  17.8
(n  281)
Treatment satisfaction 75.4  14.0
(n  281)
edical history, n (%)
History of unstable angina 98 (35)
History of congestive heart failure 145 (51)
NYHA functional class I 38 (13)
NYHA functional class II 86 (30)
NYHA functional class III 21 (7)
NYHA functional class IV 0
Diabetes mellitus 54 (19)
Insulin-dependent 2 (1)
Previous myocardial infarction 233 (82)
Previous coronary artery bypass grafting 34 (12)
Previous percutaneous coronary intervention 25 (9)
Intermittent claudication 32 (11)
Hypertension 257 (91)
Analysis of variance with effects for treatment and pooled site. †Cochran-Mantel-Haensze
ank scores, stratifying by pooled site.
LAN  long-acting nitrate; NC  not calculated; NTG  nitroglycerin; NYHA  N
eviation; SE  standard error.able 2. Concomitant Medications
Drug, n (%)
Placebo 
Amlodipine
(n  283)
Ranolazine 
Amlodipine
(n  281)
spirin 244 (86) 245 (87)
CE inhibitors 144 (51) 152 (54)
AN 123 (43) 130 (46)
tatins 93 (33) 109 (39)
iuretics 77 (27) 89 (32)
ntidiabetics
(including insulin)
29 (10) 33 (12)umption between treatment groups were noted. A non-
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Ranolazine for Stable Angina August 1, 2006:566–75arametric analysis based on the technique described by
och et al. (23) that adjusted for baseline values yielded a
reatment effect p value of 0.033. This confirmed the result
igure 3. Number of weekly angina attacks (A) and number of weekly
itroglycerin uses (B), excluding patients with weekly angina rate in the top
Table 3. Weekly Angina Frequency and Nitro
Placebo (
Weekly angina frequency
Trimmed mean  SE 3.31 
Arithmetic mean  SE 4.30 
25th percentile 1.47
Median 2.43
75th percentile 4.17
Weekly nitroglycerin consumption
Trimmed mean  SE 2.68 
Arithmetic mean  SE 3.57 
25th percentile 0.50
Median 1.67
75th percentile 4.00
*Cochran-Mantel-Haenszel mean scores test using rank sco
SE  standard error.n
% and bottom 2% of each treatment group (trimmed mean). SE 
tandard error of the trimmed mean.f the main analysis of nitroglycerin consumption, because
he treatment effect was still significant when a baseline
djustment was made.
The scores on the angina frequency dimension of the
AQ (dimension 1) were significantly improved in patients
eceiving ranolazine treatment compared with those receiv-
ng placebo (22.5 19.0 vs. 18.5 18.8; p 0.008). None
f the other dimensions of the SAQ was significantly
ifferent between treatment groups.
ubgroup analyses results. BASELINE SYMPTOM SEVERI-
Y. The median angina weekly episode rate at baseline was
.5 per week. Subgroup analysis showed statistically signif-
cant reductions of angina frequency, nitroglycerin use, and
AQ angina frequency for patients with a baseline fre-
uency 4.5 per week, but only of angina frequency for
hose with baseline frequency 4.5 per week (Fig. 4).
ANS, GENDER, AND AGE. These data include the first
eported experience of ranolazine in combination with
ANs. The LANs were used by 253 (45%) of the 564
atients assessed (123 patients in the placebo group and 130
atients in the ranolazine group). The mean daily dosage of
ANs (isosorbide mononitrate) was 45.4 mg/day and was
imilar between groups.
The efficacy analyses by subgroup for the primary efficacy
nd point are shown in Table 4. The differences between
reatment groups observed in the subgroups of concomitant
AN users, gender, and age were numerically similar for the
opulation as a whole. The study was not powered for
esting treatment effects within subgroups. Statistical testing
or the presence of treatment by subgroup interaction using
n analysis of variance of rank scores did not provide any
vidence that the treatment effect differed between sub-
roups. However, the power of such interaction tests is low.
ffect on heart rate and blood pressure. Vital signs
emained relatively constant over the course of treatment in
oth treatment groups, and there were no significant dif-
erences between groups (Table 5). The impact of ranola-
ine treatment on postural changes (supine to standing) was
rin Consumption
81) Ranolazine (n  277) p Value*
2.88  0.19 0.028
3.29  0.26
1.24
2.18
3.66
2.03  0.20 0.014
2.72  0.38
0.47
1.34
2.48
atifying by pooled site.glyce
n  2
0.22
0.64
0.22
0.54ot clinically significant and was similar to that of placebo.
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August 1, 2006:566–75 Ranolazine for Stable Anginaafety analyses. There were no clinically significant labo-
atory or physical examination abnormalities. The AEs
ccurred in 35.3% of placebo- and 39.9% of ranolazine-
reated patients, and most were mild to moderate in severity.
onstipation was the most frequently reported AE (8.9%
anolazine patients vs. 1.8% placebo patients) followed by
eripheral edema (5.7% ranolazine patients vs. 2.8% placebo
atients), dizziness (3.9% ranolazine patients vs. 2.5% pla-
ebo patients), nausea (2.8% ranolazine patients vs. 0.7%
lacebo patients), and headache (2.8% ranolazine patients
s. 2.5% placebo patients).
Among ranolazine-treated patients, the overall incidence,
igure 4. Number of weekly angina attacks (A) and change from baseline i
atients with baseline median angina attack rates of 4.5 and 4.5 per wype, and frequency of AEs between LAN versus non-LAN ras similar. Overall, more women than men in both
anolazine and placebo groups reported an AE. Constipa-
ion was reported by more women (15.0%) than men (6.5%)
n the ranolazine group. Peripheral edema was reported by
ore women than men in both ranolazine (7.5% vs. 5.0%)
nd placebo (5.2% vs. 1.9%) groups. As might be expected,
Es were more frequently reported by older patients (65
ears) receiving ranolazine than by younger patients (65
ears), with constipation more prevalent among older patients.
Seven patients (3 ranolazine treated; 4 placebo treated)
iscontinued the study because of AEs. One patient from
ach treatment group died during the study. The
ttle Angina Questionnaire (SAQ) angina frequency domain scores (B) for
ithin each treatment group (trimmed mean).n Sea
eek wanolazine-treated patient died as a result of pneumonia and
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Ranolazine for Stable Angina August 1, 2006:566–75ubsequent cardiopulmonary arrest 10 days after starting
anolazine treatment; however, this death was determined
o be unrelated to the study medication. The placebo-
reated patient died of an acute myocardial infarction 28
ays after beginning the double-blind treatment phase. No
ases of torsades de pointes were reported.
Cardiovascular events were collected only if they were
eported as an AE. The incidence of cardiac AEs was 5.7%
n ranolazine- versus 7.8% in placebo-treated patients.
here were no reports of unstable angina or stroke in either
reatment group. Myocardial infarction and congestive heart
ailure were each reported in 0.4% of ranolazine- versus
.7% of placebo-treated patients. Other cardiovascular
vents that occurred with an incidence of 1% in either
reatment group included: ventricular extrasystoles (1.1% of
anolazine vs. 1.1% of placebo patients), sinus bradycardia
0.7% of ranolazine vs. 1.1% of placebo patients), sinus
achycardia (0% of ranolazine vs. 1.4% of placebo patients),
achycardia (1.1% of ranolazine vs. 0.4% of placebo pa-
ients), and first-degree AV block (0% of ranolazine vs.
.1% of placebo patients).
ISCUSSION
anolazine has shown efficacy as an antianginal agent when
sed alone (17–19) and when used as part of a combination
able 4. Primary Efficacy End Point Stratified by Subgroup (LA
Placebo
Parameter LAN Users
eekly angina attacks, trimmed mean  SE 3.70  0.41
(n  122)
omparison to placebo
Women
eekly angina attacks, trimmed mean  SE 3.48  0.45
(n  76)
omparison to placebo
Age <65 yrs
eekly angina attacks, trimmed mean  SE 3.30  0.27
(n  166)
omparison to placebo
Cochran-Mantel-Haenszel mean scores test using rank scores, stratifying by pooled
LAN  long-acting nitrate; SE  standard error.
Table 5. Mean Change From Baseline  SD
Blind Treatment Phase
Parameter Placebo  Amlodi
Supine measurements
Heart rate, beats/min 1.6  9.0
Systolic BP, mm Hg 1.7  10.7
Diastolic BP, mm Hg 0.6  7.6
Standing measurements
Heart rate, beats/min 1.1  8.7
Systolic BP, mm Hg 1.8  11.6
Diastolic BP, mm Hg 0.6  7.9*Analysis of variance with effects for treatment and pooled site.
BP  blood pressure; SD  standard deviation.herapy regimen with conventional doses of other agents
20). The ERICA trial expands on the findings of previous
tudies (Table 6) by demonstrating that ranolazine provided
dditional antianginal benefit in patients who remained
ymptomatic despite treatment with a maximum recom-
ended dosage of the calcium-channel blocker amlodipine.
he present results are also the first to demonstrate incre-
ental antianginal effects with ranolazine in patients treated
ith amlodipine in combination with LANs.
As monotherapy, ranolazine has been effective to reduce
ngina frequency and improve exercise performance in
atients with stable CAD (17,18). In the Monotherapy
ssessment of Ranolazine in Stable Angina (17) study, 191
atients with chronic stable angina demonstrated significant
ncreases in exercise parameters with ranolazine 500 mg,
,000 mg, or 1,500 mg twice a day compared with placebo,
ithout clinically meaningful changes in heart rate or blood
ressure. Ranolazine was as effective as 100 mg/day atenolol
n reducing angina frequency and nitroglycerin consumption
nd improving exercise time to the onset of 1 mm ST-
egment depression and was more effective than atenolol in
rolonging the total exercise duration (18).
In combination with conventional daily doses of amlo-
ipine (5 mg), atenolol (50 mg), or diltiazem (180 mg), the
ddition of ranolazine improved total exercise time, time to
e, Gender, and Age)
mlodipine Ranolazine  Amlodipine
LAN Nonusers LAN Users LAN Nonusers
2.99  0.26 3.26  0.39 2.64  0.21
(n  159) (n  129) (n  148)
p  0.15* p  0.16*
Men Women Men
3.19  0.24 2.86  0.41 2.91  0.23
(n  205) (n  79) (n  198)
p  0.33* p  0.026*
Age >65 yrs Age <65 yrs Age >65 yrs
3.25  0.38 2.83  0.25 2.91  0.34
(n  115) (n  162) (n  115)
p  0.074* p  0.15*
tal Signs at the End of the 6-Week Double-
Ranolazine  Amlodipine p Value*
2.0  9.2 0.66
2.0  10.0 0.72
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1.8  9.7 0.39
2.9  10.9 0.24
0.6  7.2 0.99N Us
 Ain Vi
pine
o
d
a
f
s
(
f
n
p
o
s
E
o
o
t
T
w
t
a
(
p
w
T
D
T
P
S
S
C
M D 
Q
573JACC Vol. 48, No. 3, 2006 Stone et al.
August 1, 2006:566–75 Ranolazine for Stable Anginanset of angina, and time to onset of 1 mm ST-segment
epression in patients with symptomatic chronic stable
ngina (20). Ranolazine also significantly reduced angina
requency by 1.2 episodes per week and nitroglycerin con-
umption by 1.3 uses per week (both p  0.001 vs. placebo)
20).
The ERICA trial data reported here expands on findings
rom previous ranolazine trials by demonstrating that sig-
ificant additional benefit was achieved with ranolazine in
atients who remained symptomatic despite maximum rec-
mmended therapy with a calcium-channel blocker. Con-
able 6. Summary of Randomized Clinical Trials With Ranolazi
MARISA CARISA
esign Double-blind, 4-period
crossover, placebo-
controlled, n  191
randomized
Double-blind, parallel
placebo-controlled,
randomized
reatments and
duration
Ranolazine ER 500,
1,000, or 1,500 mg
or placebo twice a
day as monotherapy
for 1 week each
Ranolazine ER at 750
or placebo twice a
weeks. Background
with diltiazem 180
atenolol 50 mg QD
amlodipine 5 mg Q
rimary efficacy
measure
Exercise duration on
treadmill at trough
ranolazine
concentration
Exercise duration on
trough ranolazine c
econdary efficacy
measures
Time to angina onset
and time to 1-mm
ST-segment
depression at trough
and peak; exercise
duration at peak
Time to angina onset
mm ST-segment d
trough and peak; fr
angina attacks; exer
at peak; frequency
ummary of efficacy
results
Exercise duration at
trough increased in
dose-dependent
fashion relative to
placebo (23.8 s,
33.7 s, 45.9 s for
500 mg, 1,000 mg,
1,500 mg dose,
respectively, p 
0.005).
Exercise duration at t
increased by 23.7 s
dose) and 24.0 s (1
dose) relative to pla
(p  0.03 and p 
respectively).
Significant, dose-
related increases in
exercise duration at
peak and in time to
angina onset and
time to 1-mm ST-
segment depression
at peak and trough.
Significant increases i
duration, time to an
and time to 1-mm
depression at peak,
to angina onset at t
Significant reductio
weekly angina frequ
nitroglycerin consu
ARISA  Combination Assessment of Ranolazine in Stable Angina; ER  ext
onotherapy Assessment of Ranolazine in Stable Angina; NTG  nitroglycerin; Q
uestionnaire; TID  three times per day.istent with other ranolazine studies (17,19–21), the wRICA trial data demonstrates that the antianginal efficacy
f ranolazine occurred without clinically significant effects
n heart rate or blood pressure. There was consistency of
reatment effect irrespective of gender, LAN use, or age.
he efficacy of the drug may have been greater in patients
ho had more frequent episodes of angina, as suggested by
he greater difference between groups in angina frequency
nd nitroglycerin use in the 75th versus 25th percentiles
Table 3) and the significant improvement compared with
lacebo in nitroglycerin use observed only in those patients
ith 4.5 angina attacks per week at baseline versus those
RAN080 ERICA
p,
823
Double-blind, 3-period
crossover, placebo-
controlled, n  158
randomized
Double blind, parallel
group, placebo-controlled,
n  565 randomized
,000 mg
r 12
ment
D,
Ranolazine IR 400 mg
TID, atenolol 100 mg
QD and placebo for 1
week each
Ranolazine ER 1,000 mg
twice a day or placebo for
6 weeks, preceded by
ranolazine ER 500 mg
twice a day or placebo for
1 week. Background
therapy with amlodipine
10 mg QD throughout
dosing and at least 4
weeks before.
ill at
tration
Time to onset of angina
during treadmill or
bicycle exercise testing
at peak ranolazine
concentration
Average weekly frequency of
angina attacks
to 1-
ion at
cy of
uration
G use
Time to 1-mm ST-
segment depression and
exercise duration at peak
ranolazine concentration
Average weekly NTG
consumption; scores in 5
dimensions of SAQ
(angina frequency,
physical limitations,
anginal stability, disease
perception, and treatment
satisfaction)
mg
g
9,
Time to onset of angina
inreased by 51.0 s
relative to placebo
(p  0.001) on
ranolazine, 39.5 s on
atenolol (p  0.001).
Angina frequency reduced
by 0.43 episodes per week
relative to placebo
(p  0.028).
cise
onset
gment
n time
.
verage
and
n.
Exercise duration and time
to 1-mm ST-segment
depression significantly
increased relative to
placebo.
NTG consumption
significantly reduced.
SAQ angina frequency
assessment significantly
improved. Other SAQ
dimensions not
significantly changed.
release; ERICA  Efficacy of Ranolazine In Chronic Angina trial; MARISA 
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Ranolazine for Stable Angina August 1, 2006:566–75ymptomatic group also experienced a significant improve-
ent from baseline in the SAQ angina frequency domain
ith ranolazine treatment compared with placebo, whereas
anolazine did not alter the change from baseline in SAQ
core in the less symptomatic group (Fig. 4B). The greater
ntianginal efficacy in patients with more frequent angina,
ithout a significant change in heart rate or blood pressure,
ay reflect the fact that these patients with more frequent
ngina may have more severe or prolonged ischemia-
ssociated myocardial dysfunction and consequent hypoper-
usion, a pathophysiologic state most likely to benefit from
he unique mechanism of action of ranolazine.
An important potential value of the unique mechanism of
ction of ranolazine is that its inclusion in a combination
egimen may be more effective than that of other conven-
ional antianginal agents whose anti-ischemic efficacy is
ased on reduction in determinants of myocardial O2
emand. Addition of a second conventional antianginal
gent to monotherapy with one of the other conventional
ntianginal agents does not always confer an improvement
n efficacy (10,11), and combination regimens with these
onventional agents may actually worsen efficacy (12,13).
he use of multiple conventional agents must also be
arefully monitored to avoid additive AEs (e.g., hypoten-
ion, bradycardia, atrioventricular nodal block) (24). Use of
new antianginal agent that uses a complementary mech-
nism of action to the existing antianginal therapies may
rovide enhanced benefit.
The magnitude of antianginal benefit observed in the
RICA trial is similar to that observed in other antianginal
rials using conventional agents. In a study of patients with
inimal or moderate anginal symptoms receiving a maxi-
um recommended therapeutic dose of a beta-blocker (9),
n additional reduction of 0.8 anginal episodes per week was
bserved when the beta-blocker was combined with a
alcium-channel blocker titrated to its maximal tolerated
ose. These data are comparable to the 0.4 episodes per
eek reduction we observed. The additional reduction in
itroglycerin use (0.7 uses per week) was also comparable to
he reduction of 0.6 uses per week observed in our study. Of
ote, however, in contrast to the improved benefits from the
ombination of ranolazine and amlodipine without a change
n heart rate or blood pressure, the benefits achieved by
ombining the beta-blocker and a calcium-channel blocker
9) were associated with significant undesirable changes in
emodynamics. Use of ranolazine may allow for more
ptimal anti-ischemic effect without excessive adverse ef-
ects on heart rate and blood pressure. In the Combination
ssessment of Ranolazine in Stable Angina study (20), the
eduction in angina and nitroglycerin use when ranolazine
as added to a regimen of 5 mg/day amlodipine was greater
han that observed in the ERICA trial, where the amlodip-
ne dose was 10 mg/day. The patient populations were
ifferent in the 2 studies, but one cannot exclude that the
igher dose of amlodipine in these refractory patients may dave somewhat limited the potential antianginal efficacy of
n additional agent such as ranolazine.
Adverse events reported with ranolazine in the ERICA
rial were infrequent and mild and similar to what have been
bserved in other studies with ranolazine. The peripheral
dema observed in both treatment groups was likely related
o the use of 10 mg/day amlodipine, because such edema is
eported in nearly 11% of patients taking this dose (25).
urthermore, amlodipine is associated with a greater inci-
ence of peripheral edema in women than men (25), a
nding confirmed in this study. Ranolazine was well toler-
ted in this trial; only 1% of patients withdrew because of a
reatment-related AE.
tudy limitations. A limitation of this study is the use of
mlodipine alone at the maximum recommended dose.
ossible future studies may investigate the role of ranolazine
hen added to a more clinically relevant combination
egimen such as maximally tolerated beta-blocker plus
mlodipine.
The short-term nature of this study (6 weeks) does not
ecessarily extrapolate to long-term efficacy. The use of
atient anginal diaries rather than ambulatory Holter mon-
tors to detect episodes of ischemia adds a subjective
omponent to the design; however, all patients had a
ocumented history of CAD and angina although exercise
esting was not conducted in this study. Because most of the
atients were white and eastern European and not neces-
arily receiving optimal medical treatment for CAD (e.g.,
nly 36% were being treated with statins, 10% had prior
ABG, and 10% had prior PCI), careful interpretation of
he data is warranted.
The lack of consistency in the magnitude of the responses
o the SAQ concerning the benefit of ranolazine was likely
ue to comprehension issues, because the SAQ was not
ulturally and linguistically validated in the locations where
he trial took place. It is also possible that the statistically
ignificant differences in angina frequency and nitroglycerin
se may not have been of sufficient importance to the
atients to manifest as significant improvements in quality
f life.
Per protocol, the patients in this study were not taking
eta-blockers, and therefore our data may be especially
pplicable to the proportion of patients who cannot tolerate
eta-blocker therapy (11% for metoprolol [26], 27% for
tenolol [6]). A recent meta-analysis has shown that,
verall, beta-blockers were equivalent to calcium-channel
lockers in reducing angina symptoms and as well tolerated
27); therefore, additional studies are warranted to deter-
ine if the present results can be extrapolated to patients
efractory to other traditional therapies, including those
atients receiving maximally tolerated doses of beta-
lockers.
onclusions. This study demonstrated that ranolazine was
n effective antianginal agent in patients with stable CAD
nd persisting angina despite a maximum recommended
osage of 10 mg/day amlodipine. The addition of 1,000 mg
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August 1, 2006:566–75 Ranolazine for Stable Anginaanolazine twice a day significantly reduced the frequency of
ngina episodes and rate of nitroglycerin consumption and
ad a consistent treatment effect across subgroups including
ender, age, and LAN use. Ranolazine was well tolerated;
ost AEs were mild to moderate, and antianginal efficacy
as unrelated to changes in blood pressure or heart rate.
anolazine is a promising anti-ischemic therapy that may
e valuable in a wide variety of subsets of patients with
AD who remain symptomatic despite treatment with
ther anti-ischemic agents.
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or a list of the ERICA trial investigators, please see the
nline version of this article.
